ProfileGDS5678 / 1417163_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 60% 62% 62% 61% 66% 62% 64% 62% 69% 62% 62% 56% 62% 63% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.6246860
GSM967853U87-EV human glioblastoma xenograft - Control 23.7209362
GSM967854U87-EV human glioblastoma xenograft - Control 33.7341862
GSM967855U87-EV human glioblastoma xenograft - Control 43.6338561
GSM967856U87-EV human glioblastoma xenograft - Control 53.9652366
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.7665662
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.8950464
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.7224662
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.2502769
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.6952762
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.7224562
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.3597356
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.7396162
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.7346463